Monitor for future clinical trial results, but note that this is an early-stage study with a relatively small funding commitment. The company remains in pre-revenue development stage.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 7 $0.4130entry
- T+1 · 7mo ago −1.94%α −4.48% · $0.4050
- T+5 · 7mo ago −5.81%α −11.14% · $0.3890
- T+20 · 7mo ago −7.26%α −17.04% · $0.3830
- T+60 · 5mo ago +14.24%α +0.97% · $0.4718
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GT Biopharma entered into an Investigator Initiated Clinical Trial Agreement with the University of Minnesota to sponsor a phase 1a/1b clinical trial of its drug candidate GTB-5550 for advanced solid tumors. The company will fund up to $3.8 million over three years for the study, which remains in the early research phase.
Key Financial Metrics
Key Facts
- GT Biopharma entered into an Investigator Initiated Clinical Trial Agreement with the University of Minnesota
- The agreement supports a phase 1a/1b clinical trial of GTB-5550 for advanced solid tumors
- GT Biopharma will fund up to $3.8 million over three years for the study
- The trial is sponsored by the University of Minnesota, not GT Biopharma
- The drug candidate GTB-5550 is in early-stage clinical development
Financial Impact
Up to $3.8 million over three years
Risk Factors
- Clinical trial may not demonstrate efficacy or safety
- High risk associated with early-stage drug development
- Limited financial resources for drug development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-015413 |
| Document: form8-k.htm | 0001493152-26-015413 |
| Document: 0001493152-26-015413-index-headers.html | 0001493152-26-015413 |
| Document: 0001493152-26-015413-index.html | 0001493152-26-015413 |
| Document: 0001493152-26-015413.txt | 0001493152-26-015413 |
Track record
12 reports on GTBP
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +41.62% at T+60 after the Aug 14, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 3/10 Entry $3.72 Now $3.54 −4.97% settles Feb 12
- Oct 21, 202627d ago EFFECT Bearish 6/10 Entry $5.41 Now $3.54 +34.66% settles Jan 19
- Oct 13, 20264w ago DEF 14A Bearish 7/10 Entry $6.21 Now $3.54 +43.08% settles Jan 11
- Oct 9, 20265w ago S-1 Bearish 7/10 Entry $6.80 Now $3.54 +48.01% settles Jan 7
- Sep 25, 20267w ago 8-K Neutral 3/10 Entry $6.80 Now $3.54 −48.01% settles Dec 22
- Sep 15, 20268w ago 8-K Bearish 7/10 Entry $9.00 Now $3.54 +60.72% settles Dec 9
- Sep 3, 202610w ago 8-K Neutral 4/10 Entry $0.2524 Now $3.54 +1300.55% settles Nov 30
- Aug 14, 202613w ago Press Release Bearish 5/10 Entry $0.2960 to $0.1728 Now $3.54 −1094.26% ▲ +41.62% +38.58% vs SPY
- May 22, 202625w ago 8-K Bearish 7/10 Entry $0.4400 to $0.2754 Now $3.54 −703.41% ▲ +37.41% +40.60% vs SPY
- Apr 30, 202628w ago S-1 Bearish 7/10 Entry $0.3430 to $0.3167 Now $3.54 −930.61% ▲ +7.67% +10.74% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers